NCI Trials for February 2021

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

Phase I – 10355

A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies

Dana-Farber – Harvard Cancer Center LAO

Lee, Elizabeth Katherine

(617) 632-5269

Phase I – A051901

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

Alliance for Clinical Trials in Oncology

Alencar, Alvaro Jose

(305) 243-4372

Phase II – EA3191

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

ECOG-ACRIN Cancer Research Group

Zandberg, Dan Paul

(412) 864-7955

Phase II – PEPN1924

A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma

Pediatric Early Phase Clinical Trial Network

Reed, Damon Russell

(813) 745-3242

Phase III – ACNS1931

A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination with Vinblastine for Non-NF1, Non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Children’s Oncology Group

Bowers, Daniel Charles

(214) 648-3896

Phase Other – A152022

Alliance COVID-19 Pandemic Study

Alliance for Clinical Trials in Oncology

Hahn, Olwen Mary

(773) 702-4400

Phase Other – S1912CD

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

SWOG

Shankaran, Veena

(206) 288-7456

Phase Pilot – PEPN21EHRPBTCN15

Pilot Study to Enable Electronic Laboratory Data Transfer Into Medidata Rave

Pediatric Early Phase Clinical Trial Network

Miller, Tamara Porter

(404) 727-9268

In This Issue

YOU MAY BE INTERESTED IN

President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H.  “The discretionary request calls for $6.5 billion to...